Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Biosyent Inc V.RX

Alternate Symbol(s):  BIOYF

Biosyent Inc is a growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products. Its products include FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn and Tibella.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 

RE:RE:share buyback

  rate and reply

BioSyent to Present

MISSISSAUGA, Ontario, April 26, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming 2022 Bloom Burton & more

RE:RE:RE:share buyback

They were a few small sales by Wilson and Raghubir around the time of the annual share grant (RSUs). Hardly cause for concern. The three discontinued products totaled less than $2M in revenue in more

RE:RE:RE:RE:share buyback

Dividend?  rate and reply

RE:RE:RE:share buyback

Why would execs exercise options with $9.12 strike price and years to expiry?     rate and reply

RE:share buyback

Nice that they still see value in buying shares back north of $8  rate and reply

share buyback

Filed 2022-04-10 09:12   Tx date 2022-03-31 $RX BioSyent Inc. Wilson, Kevin 5 - Senior Officer of Issuer Direct Ownership more


Not since June 2018 has RX traded in double digits. I do agree that there was a period of sketchy trading about a month ago, however, the last couple of weeks appear to be showing a more more

Sketchy trading

      Date & Time Price ($) Shares Change ($) Buyer Seller more

RE:Bloom Burton raises TP to $10

eps Forecast: 2022..... $0.54      2023......$0.60      2024......$0.66          rate and reply

Bloom Burton raises TP to $10

From $8.50  rate and reply

Raymond James - cantechletter

Praises management  while wishing they would put their cash to use IMO Take a pass on BioSyent, says Raymond James By Geordie Carragher Published on March 11, 2022 more

RE:Return to Glory Days

Beat Bloom Burton's forecast of $26.9 mil rev, $7.9 mil ebitda, $0.39 eps.  rate and reply

RE:Return to Glory Days

Yup, that was quite a good quarter.  I can only imagine how well the company will do once they get full access to health care professionals once again.  Kudos to RX mgmt. And, I think more

RE:Return to Glory Days

Long time coming....     Revenue eps 2021 28,618,218 $0.49 more

Return to Glory Days

MISSISSAUGA, Ontario, March 09, 2022 (GLOBE NEWSWIRE) --  BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and twelve more

Earnings After Close Today

MISSISSAUGA, Ontario, March 03, 2022 (GLOBE NEWSWIRE) --  BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the more

Interesting New By-Law

MISSISSAUGA, Ontario, Feb. 11, 2022 (GLOBE NEWSWIRE) --  BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that its Board of Directors has approved more

RE:Normal Course Issuer Bid - Continues

  rate and reply

RE:RE:Normal Course Issuer Bid - Continues

Maybe we'll be down to 5 million shares when they pay the special dividend of $1. Won't cost them so much  rate and reply